List of Dayvigo drug patents
Dayvigo is owned by Eisai Inc.
Dayvigo contains Lemborexant.
Dayvigo has a total of 2 drug patents out of which 0 drug patents have expired.
Dayvigo was authorised for market use on 07 April, 2020.
Dayvigo is available in tablet;oral dosage forms.
Dayvigo can be used as treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
Drug patent challenges can be filed against Dayvigo from 2024-04-07.
The generics of Dayvigo are possible to be released after 21 October, 2035.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8268848 | EISAI INC | Cyclopropane compound |
Sep, 2031
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10188652 | EISAI INC | Compositions and methods for treating insomnia |
Oct, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Apr 7, 2025 |
Drugs and Companies using LEMBOREXANT ingredient
NCE-1 date: 2024-04-07
Market Authorisation Date: 07 April, 2020
Treatment: Treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance
Dosage: TABLET;ORAL
DAYVIGO family patents
8
United States
5
Japan
3
Singapore
2
Israel
2
Mexico
2
Australia
2
Russia
2
Brazil
2
Spain
2
Korea, Republic of
2
China
2
Canada
2
European Union
1
Denmark
1
Jordan
1
Hong Kong
1
Slovenia
1
Morocco
1
Colombia
1
Croatia
1
Argentina
1
Portugal
1
Cyprus
1
Malaysia
1
Peru
1
Poland
1
Chile
1
Taiwan, Province of China
1
RS
1
Ukraine
1
Tunisia
1
New Zealand
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic